Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Holdings Lowered by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 55.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,342 shares of the medical equipment provider’s stock after selling 10,457 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Zimmer Biomet were worth $881,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Dunhill Financial LLC grew its position in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet in the 4th quarter worth approximately $25,000. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the 3rd quarter worth approximately $28,000. Brooklyn Investment Group bought a new position in Zimmer Biomet in the 3rd quarter worth approximately $35,000. Finally, Kentucky Trust Co bought a new position in shares of Zimmer Biomet in the fourth quarter worth $39,000. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ZBH. Truist Financial reissued a “hold” rating and set a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Raymond James lowered their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays lowered their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Finally, JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $124.15.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.95% of the company’s stock.

Zimmer Biomet Stock Up 1.9 %

ZBH stock opened at $110.08 on Tuesday. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90. The company has a fifty day simple moving average of $105.65 and a 200 day simple moving average of $107.13. The firm has a market cap of $21.91 billion, a PE ratio of 24.74, a PEG ratio of 1.95 and a beta of 1.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the company posted $2.20 earnings per share. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.